Intended for healthcare professionals

Feature Medical Cannabis

Industry’s plan to accelerate prescribing of medical cannabis

BMJ 2020; 368 doi: (Published 18 March 2020) Cite this as: BMJ 2020;368:m1063

Linked Feature

Big cannabis in the UK: is industry support for wider patient access motivated by promises of recreational market worth billions?

Linked Feature

Tobacco cash behind cannabis research in Oxford

  1. Richard Hurley, features and debate editor
  1. The BMJ, London, UK
  1. rhurley{at}

Investors are key to increasing patients’ access to cannabis products, Richard Hurley heard at the launch of a cannabis hedge fund

The medical profession, the NHS, the National Institute for Health and Clinical Excellence (NICE), and the civil service have delivered “almost glacial” progress in the prescribing of medical cannabis, a panel agreed at the launch of a UK hedge fund for the nascent business.

Panellists, including the Conservative MP Crispin Blunt, called for investors to fund lobbying for faster change to benefit patients—and speculators.

Dubbing itself the first such UK fund, JPD Capital welcomed potential investors to the top of the Gherkin tower earlier this year. On the 40th floor, against a 360° backdrop of the city of London, they were treated to champagne, canapes, and a panel brimming with enthusiasm for the unlicensed treatments.

JPD owns fledgling cannabis businesses in Zimbabwe and Antigua and is planning “strategic acquisitions” and growth by “investing in high potential cannabis companies from seed to sale.”

A minimum stake from investors of £25 000 (€28 000; $31 000) could yield “double digit returns annually,” with “minimal risk,” the fund’s chief executive, Jon-Paul …

View Full Text

Log in

Log in through your institution


* For online subscription